COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient w...

Descripción completa

Detalles Bibliográficos
Autores principales: Barahona-Correa, Julián E, Rueda-Ortiz, Camilo, López, María-José, Gualtero, Sandra, Arevalo-Zambrano, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834623/
https://www.ncbi.nlm.nih.gov/pubmed/36643709
http://dx.doi.org/10.1177/2050313X221148548
_version_ 1784868502209822720
author Barahona-Correa, Julián E
Rueda-Ortiz, Camilo
López, María-José
Gualtero, Sandra
Arevalo-Zambrano, Mónica
author_facet Barahona-Correa, Julián E
Rueda-Ortiz, Camilo
López, María-José
Gualtero, Sandra
Arevalo-Zambrano, Mónica
author_sort Barahona-Correa, Julián E
collection PubMed
description Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
format Online
Article
Text
id pubmed-9834623
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-98346232023-01-13 COVID-19 infection during blinatumomab therapy: Is safety a dilemma? Barahona-Correa, Julián E Rueda-Ortiz, Camilo López, María-José Gualtero, Sandra Arevalo-Zambrano, Mónica SAGE Open Med Case Rep Case Report Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay. SAGE Publications 2023-01-10 /pmc/articles/PMC9834623/ /pubmed/36643709 http://dx.doi.org/10.1177/2050313X221148548 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Barahona-Correa, Julián E
Rueda-Ortiz, Camilo
López, María-José
Gualtero, Sandra
Arevalo-Zambrano, Mónica
COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title_full COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title_fullStr COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title_full_unstemmed COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title_short COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
title_sort covid-19 infection during blinatumomab therapy: is safety a dilemma?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834623/
https://www.ncbi.nlm.nih.gov/pubmed/36643709
http://dx.doi.org/10.1177/2050313X221148548
work_keys_str_mv AT barahonacorreajuliane covid19infectionduringblinatumomabtherapyissafetyadilemma
AT ruedaortizcamilo covid19infectionduringblinatumomabtherapyissafetyadilemma
AT lopezmariajose covid19infectionduringblinatumomabtherapyissafetyadilemma
AT gualterosandra covid19infectionduringblinatumomabtherapyissafetyadilemma
AT arevalozambranomonica covid19infectionduringblinatumomabtherapyissafetyadilemma

Ejemplares similares